New York Attorney General Letitia James announced that the company knowingly dispensed excess insulin to customers while misrepresenting the amounts in its billing records. Out of the total settlement, $25.1 million will be distributed to Medicaid programs across participating states, with New York’s share totaling $2.3 million.

CVS representatives expressed satisfaction with the resolution, citing the inherent difficulty of navigating insulin dosing variability and complex payor supply limits. The company noted that it had reached the agreement in principle last December, effectively ending the litigation over its prescription reporting procedures.